{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:53:22Z","timestamp":1785873202386,"version":"3.56.0"},"reference-count":116,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.phrs.2023.107036","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T13:38:31Z","timestamp":1702388311000},"page":"107036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases"],"prefix":"10.1016","volume":"199","author":[{"suffix":"Jr.","given":"Robert","family":"Roskoski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2023.107036_bib1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrd773","article-title":"Protein kinases \u2013 the major drug targets of the twenty-first century?","volume":"1","author":"Cohen","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2023.107036_bib2","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2023.107036_bib3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2023.107036_bib4","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.tips.2019.09.002","article-title":"The landscape of atypical and eukaryotic protein kinases","volume":"40","author":"Kanev","year":"2019","journal-title":"Trends Pharm. Sci."},{"key":"10.1016\/j.phrs.2023.107036_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23040908","article-title":"PKIDB: a curated, annotated and updated database of protein kinase inhibitors in clinical trials","volume":"23","author":"Carles","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2023.107036_bib6","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.phrs.2023.107036_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105579","article-title":"Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies","volume":"168","author":"Roskoski","year":"2021","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2023.107036_bib8","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.chembiol.2014.08.013","article-title":"Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates","volume":"21","author":"Doak","year":"2014","journal-title":"Chem. Biol."},{"key":"10.1016\/j.phrs.2023.107036_bib9","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1021\/acs.jmedchem.5b01273","article-title":"AXL inhibitors in cancer: a medicinal chemistry perspective","volume":"59","author":"Myers","year":"2016","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2023.107036_bib10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nrd1346","article-title":"Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia","volume":"3","author":"Roth","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2023.107036_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104609","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update","volume":"152","author":"Roskoski","year":"2020","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2023.107036_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105463","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update","volume":"165","author":"Roskoski","year":"2021","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2023.107036_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.106037","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2022 update","volume":"175","author":"Roskoski","year":"2022","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2023.107036_bib14","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.1862342","article-title":"Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2023.107036_bib15","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1126\/science.1862343","article-title":"Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase","volume":"253","author":"Knighton","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.phrs.2023.107036_bib16","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1098\/rstb.2012.0054","article-title":"Evolution of the eukaryotic protein kinases as dynamic molecular switches","volume":"367","author":"Taylor","year":"2012","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.phrs.2023.107036_bib17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1126\/science.3291115","article-title":"The protein kinase family: Conserved features and deduced phylogeny of the catalytic domains","volume":"241","author":"Hanks","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.phrs.2023.107036_bib18","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.molcel.2004.08.024","article-title":"Regulation of protein kinases; controlling activity through activation segment conformation","volume":"15","author":"Nolen","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2023.107036_bib19","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/0006-291X(92)90812-Y","article-title":"A highly conserved tyrosine residue at codon 845 within the kinase domain is not required for the transforming activity of human epidermal growth factor receptor","volume":"186","author":"Gotoh","year":"1992","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.phrs.2023.107036_bib20","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1073\/pnas.96.4.1415","article-title":"Mechanism of biological synergy between cellular Src and epidermal growth factor receptor","volume":"96","author":"Tice","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2023.107036_bib21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0092-8674(02)00741-9","article-title":"The conformational plasticity of protein kinases","volume":"109","author":"Huse","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2023.107036_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001680","article-title":"Deciphering the structural basis of eukaryotic protein kinase regulation","volume":"11","author":"Meharena","year":"2013","journal-title":"PLoS Biol."},{"key":"10.1016\/j.phrs.2023.107036_bib23","doi-asserted-by":"crossref","first-page":"17783","DOI":"10.1073\/pnas.0607656103","article-title":"Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism","volume":"103","author":"Kornev","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2023.107036_bib24","doi-asserted-by":"crossref","first-page":"14377","DOI":"10.1073\/pnas.0807988105","article-title":"A helix scaffold for the assembly of active protein kinases","volume":"105","author":"Kornev","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2023.107036_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105660","article-title":"Hydrophobic and polar interactions of FDA-approved small molecule protein kinase inhibitors with their target enzymes","volume":"169","author":"Roskoski","year":"2021","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2023.107036_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106552","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2023 update","volume":"187","author":"Roskoski","year":"2023","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2023.107036_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105422","article-title":"Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs)","volume":"165","author":"Roskoski","year":"2021","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2023.107036_bib28","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1146\/annurev.bi.62.070193.002321","article-title":"Signaling by receptor tyrosine kinases","volume":"62","author":"Fantl","year":"1993","journal-title":"Annu Rev. Biochem"},{"key":"10.1016\/j.phrs.2023.107036_bib29","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/1097-0142(19830515)51:10<1787::AID-CNCR2820511004>3.0.CO;2-A","article-title":"The epidermal growth factor (EGF)","volume":"51","author":"Cohen","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.phrs.2023.107036_bib30","doi-asserted-by":"crossref","first-page":"7709","DOI":"10.1016\/S0021-9258(19)38983-5","article-title":"Epidermal growth factor","volume":"265","author":"Carpenter","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2023.107036_bib31","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0021-9258(19)68224-4","article-title":"A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles","volume":"257","author":"Cohen","year":"1982","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2023.107036_bib32","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3389\/fcell.2016.00088","article-title":"The under-appreciated promiscuity of the epidermal growth factor receptor family","volume":"4","author":"Kennedy","year":"2016","journal-title":"Front Cell Dev. Biol."},{"key":"10.1016\/j.phrs.2023.107036_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2004.04.150","article-title":"The ErbB\/HER receptor protein-tyrosine kinases and cancer","volume":"319","author":"Roskoski","year":"2004","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.phrs.2023.107036_bib34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2023.107036_bib35","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.phrs.2014.06.001","article-title":"ErbB\/HER protein-tyrosine kinases: structures and small molecule inhibitors","volume":"87","author":"Roskoski","year":"2014","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2023.107036_bib36","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","article-title":"Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2023.107036_bib37","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/312513a0","article-title":"The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen","volume":"312","author":"Schechter","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2023.107036_bib38","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/309418a0","article-title":"Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells","volume":"309","author":"Ullrich","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2023.107036_bib39","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1056\/NEJMra0802714","article-title":"Lung cancer","volume":"359","author":"Herbst","year":"2008","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2023.107036_bib40","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.lungcan.2013.01.018","article-title":"Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance","volume":"80","author":"Massarelli","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.phrs.2023.107036_bib41","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/1097-0142(19840201)53:3+<630::AID-CNCR2820531308>3.0.CO;2-3","article-title":"Steroid-hormone receptors in breast cancer","volume":"53","author":"Wittliff","year":"1984","journal-title":"Cancer"},{"key":"10.1016\/j.phrs.2023.107036_bib42","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2023.107036_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106362","article-title":"Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders","volume":"183","author":"Roskoski","year":"2022","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2023.107036_bib44","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.semcdb.2008.07.020","article-title":"The JAK kinases: not just another kinase drug discovery target","volume":"19","author":"Wilks","year":"2008","journal-title":"Semin Cell Dev. Biol."},{"key":"10.1016\/j.phrs.2023.107036_bib45","doi-asserted-by":"crossref","first-page":"6374","DOI":"10.1073\/pnas.91.14.6374","article-title":"Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes","volume":"91","author":"Kawamura","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2023.107036_bib46","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2023.107036_bib47","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.critrevonc.2007.01.006","article-title":"Vascular endothelial growth factor (VEGF) signaling in tumor progression","volume":"62","author":"Roskoski","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"3","key":"10.1016\/j.phrs.2023.107036_bib48","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bbrc.2008.07.121","article-title":"VEGF receptor protein-tyrosine kinases: structure and regulation","volume":"375","author":"Roskoski","year":"2008","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.phrs.2023.107036_bib49","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.phrs.2017.03.010","article-title":"Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas","volume":"120","author":"Roskoski","year":"2017","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2023.107036_bib50","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41573-023-00671-z","article-title":"Targeting angiogenesis in oncology, ophthalmology and beyond","volume":"22","author":"Cao","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2023.107036_bib51","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41580-023-00631-w","article-title":"Biology and therapeutic targeting of vascular endothelial growth factor A","volume":"24","author":"P\u00e9rez-Guti\u00e9rrez","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.phrs.2023.107036_bib52","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2023.107036_bib53","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.phrs.2023.107036_bib54","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.3390\/biom13101490","article-title":"Multifaceted roles of ALK family receptors and augmentor ligands in health and disease: a Comprehensive Review","volume":"13","author":"Katic","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.phrs.2023.107036_bib55","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.phrs.2012.11.007","article-title":"Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition","volume":"68","author":"Roskoski","year":"2013","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2023.107036_bib56","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.phrs.2017.01.007","article-title":"Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers","volume":"117","author":"Roskoski","year":"2017","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2023.107036_bib57","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1517\/17460441.2013.813015","article-title":"The preclinical profile of crizotinib in the treatment of non-small cell lung cancer and other neoplastic disorders","volume":"8","author":"Roskoski","year":"2013","journal-title":"Expert Opin. Drug Dis."},{"key":"10.1016\/j.phrs.2023.107036_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106156","article-title":"Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia","volume":"178","author":"Roskoski","year":"2022","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2023.107036_bib59","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2023.107036_bib60","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0092-8674(84)90077-1","article-title":"Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22","volume":"36","author":"Groffen","year":"1984","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2023.107036_bib61","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.bbrc.2003.08.055","article-title":"STI-571: an anticancer protein-tyrosine kinase inhibitor","volume":"309","author":"Roskoski","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2023.107036_bib62","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0092-8674(03)00191-0","article-title":"A myristoyl\/phosphotyrosine switch regulates c-Abl","volume":"112","author":"Hantschel","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2023.107036_bib63","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1146\/annurev-biochem-090308-173656","article-title":"The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling","volume":"80","author":"Dar","year":"2011","journal-title":"Annu Rev. Biochem"},{"key":"10.1016\/j.phrs.2023.107036_bib64","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1021\/jm901443h","article-title":"Through the \"gatekeeper door\": exploiting the active kinase conformation","volume":"53","author":"Zuccotto","year":"2010","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2023.107036_bib65","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1039\/C2MD20180A","article-title":"Approaches to discover non-ATP site inhibitors","volume":"4","author":"Gavrin","year":"2013","journal-title":"Med Chem. Commun."},{"key":"10.1016\/j.phrs.2023.107036_bib66","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.2174\/138161212800672813","article-title":"New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors","volume":"18","author":"Lamba","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2023.107036_bib67","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1021\/jm0608107","article-title":"Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors","volume":"50","author":"Liao","year":"2007","journal-title":"J. Med Chem."},{"key":"10.1016\/j.phrs.2023.107036_bib68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","article-title":"A historical overview of protein kinases and their targeted small molecule inhibitors","volume":"100","author":"Roskoski","year":"2015","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2023.107036_bib69","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.phrs.2018.01.021","article-title":"The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders","volume":"129","author":"Roskoski","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2023.107036_bib70","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2023.107036_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104567","article-title":"The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder","volume":"151","author":"Roskoski","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2023.107036_bib72","doi-asserted-by":"crossref","first-page":"15694","DOI":"10.1074\/jbc.M601252200","article-title":"Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family","volume":"281","author":"Zhang","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2023.107036_bib73","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/wdev.176","article-title":"The fibroblast growth factor signaling pathway","volume":"4","author":"Ornitz","year":"2015","journal-title":"Wiley Inter. Rev. Dev. Biol."},{"key":"10.1016\/j.phrs.2023.107036_bib74","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2023.107036_bib75","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.phrs.2018.11.035","article-title":"Cyclin-dependent protein serine\/threonine kinase inhibitors as anticancer drugs","volume":"139","author":"Roskoski","year":"2019","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2023.107036_bib76","doi-asserted-by":"crossref","first-page":"9494","DOI":"10.1021\/bi0009643","article-title":"On the concentrations of cyclins and cyclin-dependent kinases in extracts of cultured human cells","volume":"39","author":"Arooz","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2023.107036_bib77","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrc3983","article-title":"The dynamic control of signal transduction networks in cancer cells","volume":"15","author":"Kolch","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2023.107036_bib78","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.02872","article-title":"Cyclin D activates the Rb tumor suppressor by mono-phosphorylation","volume":"3","author":"Narasimha","year":"2014","journal-title":"Elife"},{"key":"10.1016\/j.phrs.2023.107036_bib79","first-page":"953","article-title":"A transmissible feline fibrosarcoma of viral origin","volume":"31","author":"McDonough","year":"1971","journal-title":"Cancer Res"},{"key":"10.1016\/j.phrs.2023.107036_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104725","article-title":"The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias","volume":"155","author":"Roskoski","year":"2020","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2023.107036_bib81","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1152\/physrev.00029.2018","article-title":"FMS-like tyrosine kinase 3\/FLT3: from basic science to clinical implications","volume":"99","author":"Kazi","year":"2019","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.phrs.2023.107036_bib82","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.tips.2022.12.007","article-title":"Futibatinib (Lytgobi) for cholangiocarcinoma","volume":"44","author":"Roskoski","year":"2023","journal-title":"Trends Pharm. Sci."},{"key":"10.1016\/j.phrs.2023.107036_bib83","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.3390\/cancers15184446","article-title":"Targetable molecular alterations in the treatment of biliary tract cancers: an overview of the available treatments","volume":"15","author":"Valery","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.phrs.2023.107036_bib84","article-title":"Clinical development and management of adverse events associated with FGFR inhibitors","volume":"4","author":"Subbiah","year":"2023","journal-title":"Cell Rep. Med"},{"key":"10.1016\/j.phrs.2023.107036_bib85","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phrs.2023.107036_bib86","doi-asserted-by":"crossref","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","article-title":"NCCN guidelines\u00ae insights: breast cancer, version 4.2023","volume":"21","author":"Gradishar","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.phrs.2023.107036_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188967","article-title":"20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight","volume":"1878","author":"Singh","year":"2023","journal-title":"Biochim Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.phrs.2023.107036_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1124167","article-title":"Guidance for clinicians and patients with non-small cell lung cancer in the time of precision medicine","volume":"13","author":"Villaruz","year":"2023","journal-title":"Front Oncol."},{"key":"10.1016\/j.phrs.2023.107036_bib89","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.12669\/pjms.38.6.5456","article-title":"Comparison of gefitinib in the treatment of patients with non-small cell lung cancer and clinical effects of osimertinib and EGFR gene mutation","volume":"38","author":"Li","year":"2022","journal-title":"Pak. J. Med Sci."},{"key":"10.1016\/j.phrs.2023.107036_bib90","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.6004\/jnccn.2022.0046","article-title":"Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Gerds","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.phrs.2023.107036_bib91","doi-asserted-by":"crossref","first-page":"6690","DOI":"10.3390\/jcm12206690","article-title":"Janus kinase inhibitors in rheumatoid arthritis: an update on the efficacy and safety of tofacitinib, baricitinib and upadacitinib","volume":"12","author":"Harrington","year":"2023","journal-title":"J. Clin. Med"},{"key":"10.1016\/j.phrs.2023.107036_bib92","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/jcpt.13282","article-title":"A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma","volume":"46","author":"Heo","year":"2021","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.phrs.2023.107036_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1223929","article-title":"Comparative safety of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis","volume":"14","author":"Krawczyk","year":"2023","journal-title":"Front Pharm."},{"key":"10.1016\/j.phrs.2023.107036_bib94","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41408-023-00823-9","article-title":"Management of chronic myeloid leukemia in 2023 - common ground and common sense","volume":"13","author":"Senapati","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.phrs.2023.107036_bib95","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cllc.2022.09.007","article-title":"Real-world treatment sequencing, toxicities, health utilities, and survival outcomes in patients with advanced ALK-rearranged non-small-cell lung cancer","volume":"24","author":"Schmid","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.phrs.2023.107036_bib96","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1200\/JCO.22.00824","article-title":"Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO living guideline","volume":"40","author":"Singh","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2023.107036_bib97","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1001\/jamaoncol.2023.2000","article-title":"Cyclin-Dependent Kinase 4\/6 inhibitors for treatment of Hormone Receptor-positive, ERBB2-negative breast cancer: a review","volume":"9","author":"O'Sullivan","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.phrs.2023.107036_bib98","first-page":"1016","article-title":"Economic evaluation of three BRAF + MEK inhibitors for the treatment of advanced unresectable melanoma with BRAF mutation from a US payer perspective","volume":"57","author":"Halloush","year":"2023","journal-title":"Ann. Pharm."},{"key":"10.1016\/j.phrs.2023.107036_bib99","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2016.09.011","article-title":"Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms","volume":"113","author":"Roskoski","year":"2016","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2023.107036_bib100","article-title":"Pirtobrutinib: First non-covalent tyrosine kinase inhibitor for treating relapsed or refractory mantle cell lymphoma in adults","author":"De","year":"2023","journal-title":"Curr. Med Chem."},{"key":"10.1016\/j.phrs.2023.107036_bib101","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1039\/D2MD00067A","article-title":"FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms","volume":"13","author":"Acharya","year":"2022","journal-title":"RSC Med Chem."},{"key":"10.1016\/j.phrs.2023.107036_bib102","first-page":"324","article-title":"Avapritinib approved for GIST subgroup","volume":"10","author":"Dolgin","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2023.107036_bib103","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/CCO.0000000000000845","article-title":"Next questions for the medical treatment of gastrointestinal stromal tumor","volume":"34","author":"Italiano","year":"2022","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.phrs.2023.107036_bib104","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s40265-020-01348-2","article-title":"Ripretinib: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2023.107036_bib105","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3390\/ph16040614","article-title":"Agnostic approvals in oncology: getting the right drug to the right patient with the right genomics","volume":"16","author":"Tateo","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.phrs.2023.107036_bib106","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0092-8674(85)90115-1","article-title":"Activation of a novel human transforming gene, ret, by DNA rearrangement","volume":"42","author":"Takahashi","year":"1985","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2023.107036_bib107","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/381789a0","article-title":"GDNF signalling through the Ret receptor tyrosine kinase","volume":"381","author":"Durbec","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2023.107036_bib108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2017.12.021","article-title":"Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers","volume":"128","author":"Roskoski","year":"2018","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2023.107036_bib109","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1080\/07357907.2023.2255655","article-title":"Efficacy and safety of RET-specific kinase inhibitors in RET-altered cancers: a systematic review","volume":"41","author":"Ali","year":"2023","journal-title":"Cancer Invest"},{"key":"10.1016\/j.phrs.2023.107036_bib110","first-page":"5693","article-title":"Financial toxicity and employment status in cancer survivors. A systematic literature review","volume":"28","author":"Mols","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.phrs.2023.107036_bib111","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1200\/JCO.2013.49.1845","article-title":"Cancer drugs in the United States: justum pretium\u2013the just price","volume":"31","author":"Kantarjian","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2023.107036_bib112","first-page":"868","article-title":"Estimated discounts generated by Medicare drug negotiation in 2026","volume":"29","author":"Hernandez","year":"2023","journal-title":"J. Manag Care Spec. Pharm."},{"key":"10.1016\/j.phrs.2023.107036_bib113","first-page":"229","article-title":"Drugs likely subject to Medicare negotiation, 2026-2028","volume":"29","author":"Dickson","year":"2023","journal-title":"J. Manag Care Spec. Pharm."},{"key":"10.1016\/j.phrs.2023.107036_bib114","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2023.1090","article-title":"Comparison of out-of-pocket spending on ultra-expensive drugs in Medicare Part D vs commercial insurance","volume":"4","author":"DiStefano","year":"2023","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.phrs.2023.107036_bib115","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1001\/jama.2023.19506","article-title":"Medicare's historic prescription drug price negotiations","volume":"330","author":"Gostin","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2023.107036_bib116","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.phrs.2017.02.005","article-title":"Guidelines for preparing color figures for everyone including the colorblind","volume":"119","author":"Roskoski","year":"2017","journal-title":"Pharm. Res"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823003924?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823003924?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:49:52Z","timestamp":1760914192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661823003924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":116,"alternative-id":["S1043661823003924"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2023.107036","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2023.107036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107036"}}